The List Price: What Keytruda Costs Before Insurance
Merck publishes its own list price — also called the wholesale acquisition cost, or WAC — directly on its patient site, and updates it periodically. As of March 2026, the figures are:
| Dosing schedule | Dose | List price per dose |
|---|---|---|
| Every 3 weeks (Q3W) | 200 mg | $12,272.00 |
| Every 6 weeks (Q6W) | 400 mg | $24,544.00 |
Notice that $24,544 is exactly double $12,272 — the 6-week dose is exactly double the 3-week dose (400 mg vs. 200 mg), so the underlying price per milligram, and the price per week of treatment, is identical either way. Your oncologist chooses the schedule based on clinical factors and convenience, not cost.
List price isn't a real-world transaction price. WAC doesn't reflect rebates, discounts negotiated with insurers and pharmacy benefit managers, 340B pricing at eligible safety-net providers, or Medicare's Average Sales Price-based reimbursement formula for Part B drugs. It's best used as a reference ceiling — roughly what you'd be billed if nothing else applied — not as a prediction of your actual bill.
Turning "Per Dose" Into "Per Month" — Show Your Work
Because a lot of people search for a "monthly cost" out of habit, here's the conversion, done transparently, using an average month length of about 4.35 weeks:
That's a calculated equivalent for comparison purposes — Merck doesn't publish a "monthly price," and no insurer bills you monthly for Keytruda. What actually shows up on a bill or an explanation of benefits is a per-infusion charge, on whatever schedule your treatment plan uses. If you see a "Keytruda monthly cost" figure elsewhere that doesn't roughly match this math, it's worth checking what dosing assumption they used.
What You'll Actually Pay With Commercial Insurance
Merck commissioned an independent analysis by Milliman, Inc. of 2021–2022 commercial and Medicare claims data for 200 mg Keytruda doses, and publishes the results directly on its cost page:
- 59% of commercially insured patients paid $0 out of pocket for a 200 mg dose.
- Of the patients who did have some out-of-pocket cost, roughly 80% paid between $0.01 and $375 per infusion, after satisfying their deductible.
The deductible is the variable that moves the most. Before you've met your plan's annual deductible, you're more likely to be billed an amount closer to your plan's negotiated rate for the drug (which is typically well below list price, though insurers don't usually disclose the exact negotiated figure). After the deductible is met, coinsurance or a flat copay for infused specialty drugs typically applies, which is where the $0–$375 range comes from for most patients.
What You'll Actually Pay With Medicare
Because Keytruda is billed under the medical benefit (Part B) rather than the pharmacy benefit, how much you pay depends heavily on whether you have Medicare Advantage, traditional Medicare with supplemental coverage, or traditional Medicare alone.
| Coverage type | Share paying $0 | Typical range if you do pay |
|---|---|---|
| Medicare Advantage | 39% | $0.01 – $1,325 |
| Traditional Medicare with supplemental (Medigap) coverage | Most costs typically covered by the supplemental plan | Varies by Medigap plan |
| Traditional Medicare, no supplemental coverage | Uncommon | $1,300 – $2,100 |
A few mechanics worth understanding here. In 2026, the annual Medicare Part B deductible is $283, and the standard Part B monthly premium is $202.90 (higher for some beneficiaries based on income). Once you've met the Part B deductible, Original Medicare typically pays 80% of the Medicare-approved amount for a covered Part B drug and you're responsible for the remaining 20% coinsurance — which is why the "no supplemental coverage" range above lands in four figures per infusion, while people with a Medigap policy often have that coinsurance covered.
Most traditional Medicare beneficiaries do carry some form of supplemental coverage, whether through a former employer or a purchased Medigap policy, which is why the "no supplemental coverage" scenario is the less common of the two traditional Medicare situations, even though it produces the highest out-of-pocket numbers.
What You'll Actually Pay With Medicaid
Medicaid cost-sharing rules are set at the federal level with some state flexibility, and are generally nominal for prescription drugs. For most Medicaid enrollees, out-of-pocket costs for a drug like Keytruda fall in the range of $4 to $8 per infusion, per federal Medicaid cost-sharing guidance. Costs can be higher for enrollees above certain income thresholds, and specifics vary by state Medicaid program.
What You'll Pay With No Insurance
Without any insurance coverage, Merck's own guidance is direct: you could be billed an amount close to the list price shown above, plus separate facility and infusion administration charges from wherever you receive treatment. This is the scenario where the $12,272 / $24,544 figures are most likely to actually reflect what you owe.
This is also the scenario where Merck's assistance programs matter most (more on those below) — the company states it provides certain medicines, including Keytruda, at no cost to eligible patients who lack prescription drug or health insurance coverage and cannot otherwise afford treatment.
Does Keytruda Qlex Cost Less?
It's a reasonable assumption that a quick subcutaneous injection would be priced lower than a 30-minute IV infusion — but according to Merck's own cost pages for both products, the list prices are identical: $12,272 per 3-week dose and $24,544 per 6-week dose for Keytruda Qlex, matching standard IV Keytruda exactly.
Where Qlex could still save you money isn't the drug charge itself — it's the administration side. A 1–2 minute subcutaneous injection generally involves less infusion-chair time and lower facility administration fees than a 30-minute IV infusion, and some patients may be able to receive it in a broader range of settings. Ask your infusion center's billing staff whether that translates into a lower facility fee for your specific site of care; the drug's own list price won't be the difference.
Ways to Lower the Cost
- Merck's Co-pay Assistance Program — for eligible commercially insured patients, this can reduce out-of-pocket cost to as little as $25 per infusion, up to an annual savings cap. Enrollment is required, and this program generally isn't available to patients on Medicare, Medicaid, or other government coverage.
- The Merck Access Program — can run a benefits investigation for your specific plan and walk you through what assistance you may qualify for. Reach the program at 855-257-3932.
- The Merck Patient Assistance Program — a separate 501(c)(3) foundation that may provide Keytruda at no cost to eligible uninsured or underinsured patients who meet income requirements. Applications are typically submitted through your oncology practice.
- Independent charitable copay foundations — organizations such as the Patient Access Network Foundation or the HealthWell Foundation periodically open disease-specific funds that can help cover coinsurance for cancer treatment, including for patients on Medicare (who generally can't use manufacturer copay cards). Fund availability changes throughout the year, so check current status directly with each foundation.
- Ask about your specific site of care — facility and infusion administration fees vary by setting (hospital outpatient department vs. independent oncology clinic vs. infusion center), and this is a separate cost from the drug itself that's sometimes negotiable or plan-dependent.
Is Keytruda Getting Cheaper Under Medicare Price Negotiation?
Not in the immediate future, though this is a more current and more complicated answer than most cost pages give.
The Inflation Reduction Act created the Medicare Drug Price Negotiation Program, which is being phased in over several years and, starting with pricing that took effect in 2028, became able to include Part B drugs (like Keytruda) for the first time, not just Part D drugs. Because of its enormous Medicare spending, Keytruda was widely expected by health policy analysts to be a near-certain selection for that 2028 pricing cycle.
That changed in 2025. The One Big Beautiful Bill Act expanded an existing "orphan drug exclusion" in the negotiation program's rules, and Keytruda's early FDA approvals originally came with orphan drug designations for specific cancer types before its label expanded to the much broader set of cancers it treats today. That expanded exclusion made Keytruda ineligible for the 2028 selection cycle. Health policy analysts now expect Keytruda to become eligible for selection in 2027, which — if it is selected — would mean negotiated pricing wouldn't take effect until 2029 at the earliest.
In plain terms: if you were expecting Medicare price negotiation to bring Keytruda's price down soon, that timeline just moved back by at least a year, and possibly longer depending on future negotiation cycles. This has no effect on commercial insurance pricing, which isn't part of the Medicare negotiation program at all.
Why There's No Single "Total Treatment Cost"
Unlike a drug with a fixed course (say, a 10-day antibiotic), Keytruda's total cost for a full course of treatment depends on how long treatment continues, which is different for nearly every patient. Depending on the specific cancer type and how the drug is being used, treatment duration in clinical practice commonly extends up to around two years, and in some settings continues until the disease progresses or side effects require stopping — there isn't one standard length. That means a meaningful "total cost of treatment" figure would have to assume a specific number of doses, which varies too much by individual case to state as a single number. If your care team can tell you the number of planned cycles for your specific treatment plan, you can multiply that by the relevant per-dose figures above to get a rough estimate.